# A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

> **NCT05705635** · PHASE2 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Gastric Adenocarcinoma
- Adenocarcinoma of Gastroesophageal Junction

## Interventions

- **DRUG:** Docetaxel for injection (Albumin-bound)
- **DRUG:** Taxotere

## Key facts

- **NCT ID:** NCT05705635
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-13
- **Primary completion:** 2023-05
- **Final completion:** 2024-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05705635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05705635, "A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05705635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*